

CITATION REPORT

List of articles citing

Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer

DOI: 10.1007/s40273-014-0207-1

Pharmacoeconomics, 2014, 32, 1231-43.

Source: <https://exaly.com/paper-pdf/58425938/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
12	Colon cancer 12-gene assay cost saving in the US. <i>Pharmacoeconomics & Outcomes News</i> , 2014 , 712, 11-13.	1	1
11	Oncotype DX(®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence. <i>Surgical Oncology</i> , 2015 , 24, 61-6	2.5	64
10	IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers. <i>Annals of Surgery</i> , 2016 , 263, 337-44	7.8	20
9	12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2906-13	2.2	47
8	Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients. <i>Value in Health</i> , 2016 , 19, 82-7	3.3	11
7	A 15-gene signature for prediction of colon cancer recurrence and prognosis based on SVM. <i>Gene</i> , 2017 , 604, 33-40	3.8	67
6	Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations. <i>Cost Effectiveness and Resource Allocation</i> , 2018 , 16, 2	2.4	18
5	Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses. <i>Oncotarget</i> , 2019 , 10, 3408-3423	3.3	5
4	Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. <i>Pharmacoeconomics</i> , 2021 , 39, 953-964	4.4	1
3	CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.. <i>Value in Health</i> , 2022 , 25, 409-418	3.3	0
2	Evaluating the quality of the economic evidence in colorectal cancer genomics studies. <i>Personalized Medicine</i> ,	2.2	
1	Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review. 2023 , 21,		0